Piper Sandler resumed coverage on Monopar Therapeutics with a new price target

3/19/25 8:17:26 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNPR

Date	Price Target	Rating	Analyst
6/23/2025	$60.00	Buy	Chardan Capital Markets
3/19/2025	$76.00	Overweight	Piper Sandler
1/10/2025	$72.00	Overweight	Piper Sandler
10/11/2024	$50.00	Buy	Rodman & Renshaw
11/1/2021	$9.00	Buy	HC Wainwright & Co.